Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
235 Clinical Trials near Montvale, NJ
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerTranscranial Photobiomodulation for Alzheimer's Disease
Orangeburg, New York
This multi-site study will be the first to evaluate the dose-dependent effects of t-PBM in amnestic Mild Cognitive Impairment (aMCI) and early Alzheimer's Disease (AD) (CDR of 0.5-1, FAST 1-4; age 65-85) in a randomized clinical trial of 8 weeks of t-PBM vs. sham. At baseline, all subjects will complete initial neuropsychological testing. To elucidate mechanisms of action of t-PBM, prior to treatment, subjects will undergo neuroimaging related to critical features of AD: tau 18F MK-6240 load (PET), measures of brain bioenergetics (31P-MRS), and functional connectivity (rs-fMRI). After undergoing target engagement testing (t-PBM session performed during fMRI to detect BOLD changes with active t-PBM), subjects will then be randomized to t-PBM/sham and complete 24 t-PBM/sham treatments, \~11 min per day, 3 days per week, for 8 weeks. t-PBM will be administered via continuous, 808 nm wavelength laser delivery to the forehead bilaterally (at standard EEG electrode positions F4, F3).
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:65 - 85
Key Eligibility Criteria
Disqualifiers:Other Dementia, Stroke, Bipolar, Others
Must Be Taking:Memantine, Acetylcholinesterase Inhibitors
196 Participants Needed
Pembrolizumab for Sarcoma
Montvale, New Jersey
The purpose of the study is to find out if pembrolizumab is a useful treatment that causes few or mild side effects in people with ultra-rare sarcoma. The researchers will also study how the immune system responds to the study treatment.
Pembrolizumab is a type of drug called a PD-1 inhibitor. It is designed to block a protein called programmed cell death protein 1 (PD-1) that usually acts as a "brake" on the immune system. Blocking this protein is like releasing the brakes, so that the immune system can target cancer cells and destroy them.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Immunodeficiency, Autoimmune Disease, Others
Must Not Be Taking:Immunosuppressants, Steroids
32 Participants Needed
Azacitidine + Venetoclax vs Stem Cell Transplant for Acute Myeloid Leukemia
Montvale, New Jersey
The researchers are doing this study to find out if an allogeneic hematopoietic stem cell transplant (HSCT) or maintenance therapy with azacitidine and venetoclax is more effective at keeping AML from coming back (relapsing).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:65+
Key Eligibility Criteria
Disqualifiers:Prior Allo-HCT, CNS Involvement, Others
Must Be Taking:Azacitidine, Venetoclax
100 Participants Needed
Melphalan + Siltuximab for Multiple Myeloma
Montvale, New Jersey
The purpose of this study is to see if siltuximab plus population pharmacokinetic (PK)-dosed melphalan works as well as the usual approach (body surface area \[BSA\]-dosed melphalan) in people with multiple myeloma (MM) who are receiving an autologous stem cell transplant (ASCT) as part of their standard treatment. The researchers will also see if siltuximab in combination with population PK-dosed melphalan works to decrease symptoms after an ASCT, and will study the safety of siltuximab.
For the run-in, 15 patients will receive siltuximab, 11 mg/kg, seven days before and 14 days after autologous hematopoietic stem cell infusion (+/-2 day).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:60+
Key Eligibility Criteria
Disqualifiers:Other Malignancy, Autoimmune Disease, Others
Must Not Be Taking:IL-6 Inhibitors
215 Participants Needed
Ulixertinib for Cancer
Montvale, New Jersey
The researchers are doing this study is to find out whether ulixertinib is an effective and safe treatment for people with histiocytic neoplasms.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:12+
Key Eligibility Criteria
Disqualifiers:Uncontrolled Conditions, Major Surgery, Others
Must Be Taking:Chemotherapy, BRAF Inhibitors, MEK Inhibitors
38 Participants Needed
Etrumadenant + Zimberelimab for Sarcoma
Montvale, New Jersey
This trial is testing a combination of two drugs, etrumadenant and zimberelimab, to treat patients with advanced dedifferentiated liposarcoma (DDLS). These patients have cancer that has come back, spread, or cannot be removed by surgery. Etrumadenant stops cancer cells from growing, while zimberelimab helps the immune system fight the cancer.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Active CNS Metastases, Uncontrolled Illness, Others
Must Not Be Taking:PD-1 Inhibitors, Adenosine Agents
16 Participants Needed
Tucatinib + Trastuzumab for Rectal Cancer
Montvale, New Jersey
This trial is testing a new treatment for people with rectal cancer. It uses two drugs, trastuzumab and tucatinib, along with standard chemotherapy. These drugs aim to block proteins that help cancer grow, while chemotherapy kills the cancer cells.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Recurrent Cancer, Active Infection, HIV, Others
Must Not Be Taking:Experimental Therapies
37 Participants Needed
Irinotecan + FOLFOX Chemotherapy for Rectal Cancer
Westwood, New Jersey
This trial is testing different treatments in patients with advanced rectal cancer to see which one is more effective at shrinking the tumor or stopping its growth, potentially avoiding surgery.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Upper Rectal Tumors, Others
Must Not Be Taking:CYP3A4 Inhibitors, CYP3A4 Inducers
783 Participants Needed
Reduced Chemoradiation for Head and Neck Cancer
Montvale, New Jersey
This trial tests a treatment for head and neck cancer that uses lower doses of radiation and chemotherapy, followed by surgery to remove lymph nodes. It aims to see if this approach is effective while causing fewer side effects.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:T4 Or N3, Prior Radiotherapy, Others
12 Participants Needed
ctDNA Testing for Oropharyngeal Cancer
Montvale, New Jersey
This trial is testing a blood test to detect tiny pieces of HPV DNA in people with throat cancer who have had surgery. The goal is to see if this test can help decide if and when they need more treatment like radiation or chemotherapy.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Metastatic Disease, Non-HPV16, Prior Radiation, Others
30 Participants Needed
RCM/OCT-Guided Radiation Therapy for Basal Cell Carcinoma
Montvale, New Jersey
This trial is testing a new way to use radiation therapy for treating basal cell carcinoma. The treatment uses an advanced imaging device to help doctors target the cancer more accurately. Researchers will also check for side effects and see how the treatment affects patients' quality of life. Electronic brachytherapy (EBT) is an emerging treatment technique for basal cell carcinoma (BCC).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Radiation Hypersensitivity, Prior Cancer Radiotherapy, Others
38 Participants Needed
Plinabulin + Pegfilgrastim for Multiple Myeloma
Montvale, New Jersey
This study will see how long it takes for white blood cell counts to return to normal in people with multiple myeloma (MM) who receive plinabulin and pegfilgrastim after undergoing an autologous hematopoietic stem cell transplant (AHCT).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Other Malignancy, Significant Infection, Cardiovascular History, Others
Must Not Be Taking:Investigational Drugs
17 Participants Needed
High-Dose Radiation Therapy for Prostate Cancer
Montvale, New Jersey
One of the usual approaches to treating intermediate-risk prostate cancer is a type of radiation therapy called SBRT (stereotactic body radiation therapy). SBRT delivers higher than standard doses of radiation over a lower number of treatment sessions. However, there is a 20% chance that intermediate-risk prostate cancer will come back after this treatment. The purpose of this study is to find out whether giving an even higher dose (a "boost" dose) of radiation directly to the main tumor and the standard dose of radiation to the rest of the prostate may cure the cancer or prevent it from coming back for a longer period of time while causing few side effects.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Male
Key Eligibility Criteria
Disqualifiers:Gleason Score >7, PSA >20, Metastatic Disease, MRI Ineligibility, Others
Must Not Be Taking:Androgen Deprivation Therapy
91 Participants Needed
ASTX727 for Peripheral Nerve Sheath Tumor
Montvale, New Jersey
The purpose of this study is to see whether the study drug ASTX727 is an effective treatment for people who have MPNST with a PCR2 mutation.
ASTX727 is a combination of two drugs (cedazuridine and decitabine) that have been designed to target cancer cells with a PCR2 mutation and to disrupt the cells' ability to survive and grow. The study researchers think that the study drug allows decitabine to work better than decitabine given alone.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:16+
Key Eligibility Criteria
Disqualifiers:Uncontrolled Diabetes, Active Infections, Cardiovascular Disease, Others
Must Not Be Taking:Antivirals, Anticancer
25 Participants Needed
Nivolumab + FOLFOX + Regorafenib for Esophageal Cancer
Montvale, New Jersey
The purpose of this study is to find out whether combining nivolumab, FOLFOX, and regorafenib may be a safe and effective treatment for people who have HER2-negative metastatic esophagogastric cancer.
Nivolumab is an antibody, like the proteins made by the immune system to protect the body from harm. Nivolumab blocks the protein PD-1 (programmed cell death receptor-1) that usually acts as a "brake" on the immune system. Blocking this protein is like releasing the brakes, so that the immune system can target cancer cells and destroy them.
FOLFOX is a combination of three standard chemotherapy drugs (leucovorin, 5-fluorouracil, and oxaliplatin) commonly used to treat your type of cancer. The drugs work by damaging the DNA in cancer cells, which can cause the cells to stop growing and die.
Regorafenib is a type of drug called a tyrosine kinase inhibitor (TKI). This drug targets the tyrosine kinase protein found in or on the surface of cancer cells that the cells need to survive and grow. Blocking this protein may stop cancer cells from growing, or cause them to grow more slowly or to shrink.
The study researchers think that combining nivolumab, FOLFOX, and regorafenib may be a more effective treatment for HER2-negative metastatic esophagogastric cancer than the usual chemotherapy treatment(s) alone.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:HER2-positive, Autoimmune Disorders, CNS Metastases, Others
Must Not Be Taking:Immunosuppressants, Anti-PD-1 Agents
39 Participants Needed
Rucaparib + Nivolumab for Leiomyosarcoma
Montvale, New Jersey
The purpose of this study is to find out whether combining the study drugs rucaparib and nivolumab may be an effective treatment for advanced and/or metastatic LMS, and whether the study treatment works as well as the standard chemotherapy for this type of cancer.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Autoimmune Disease, HIV, Others
Must Not Be Taking:Steroids, PARP Inhibitors
20 Participants Needed
Triple Therapy for Colorectal Cancer
Montvale, New Jersey
This study will test whether the combination of cisplatin, nivolumab, and temozolomide is an effective treatment for in people with advanced and/or metastatic colorectal cancer that is mismatch repair-proficient (MMR-proficient). The researchers will also look at how safe the study drug combination is in participants.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Immunodeficiency, Active CNS Metastases, Autoimmune, Others
Must Not Be Taking:Immunosuppressants, Steroids
18 Participants Needed
Palbociclib + INCMGA00012 for Liposarcoma
Montvale, New Jersey
The researchers are doing this study to find out whether combining the study drugs palbociclib and INCMGA00012 is an effective and safe treatment for advanced liposarcoma.
"Funding Source - FDA OOPD"
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Uncontrolled Illness, Autoimmune Disease, Others
Must Not Be Taking:CDK4 Inhibitors, Anti-PD-1/PD-L1
42 Participants Needed
Ruxolitinib + TKI for CML
Montvale, New Jersey
The purpose of this study is to determine if adding Ruxolitinib to a Tyrone Kinase Inhibitor (TKI), prior to a second attempt at stopping a TKI will lead to prolonged treatment free remission (TFR).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Accelerated CML, TKI Resistance, Others
Must Be Taking:Tyrosine Kinase Inhibitors
24 Participants Needed
Quadruple Therapy + Stem Cell Transplant for Multiple Myeloma
Montvale, New Jersey
The purpose of this study is to test any good and bad effects of giving a combination of study drugs before and after autologous stem cell transplant.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Plasma Cell Leukemia, POEMS Syndrome, Others
41 Participants Needed
Why Other Patients Applied
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
HZ
Arthritis PatientAge: 78
"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."
FF
ADHD PatientAge: 31
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
Hormone Therapy + Medications for Prostate Cancer
Montvale, New Jersey
The purpose of this study is to test if treatment with medications that reduce the male hormone level in the participant's body for a few months before surgery can shrink prostate cancer as much as possible, which might reduce the chances of the cancer coming back in the future. These treatments include a hormone injection given monthly or every three months and the study drugs, which include abiraterone acetate, prednisone, and apalutamide.
These medications are being used in combination with surgery and maybe radiotherapy because studies have shown that any single approach on its own is not sufficient to control or get rid of the cancer especially if they have high risk or aggressive features. The researchers hope to learn if combining the study drugs with surgery and radiation will get rid of the cancer from participants' prostates and reduce their prostate-specific antigen (PSA) to an undetectable level.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Sex:Male
Key Eligibility Criteria
Disqualifiers:Prior Chemotherapy, Brain Metastasis, Others
Must Be Taking:Hormone Therapy
102 Participants Needed
Olaparib for Metastatic Breast Cancer
Montvale, New Jersey
This research study is for patients with metastatic breast cancer.
* Metastatic means that the cancer has spread beyond the breast. In addition, through genetic testing of the blood or tumor, an altered gene has been found that suggests the tumor may not be able to repair its genetic material (DNA) when it becomes damaged.
* This aspect of the cancer may cause it to be more sensitive - that is, more effectively killed by certain types of drugs such as the study agent being evaluated in this trial, Olaparib.
* Olaparib is a type of drug known as a PARP inhibitor. Some types of breast cancer and ovarian cancer share some basic features that make them sensitive to similar treatments. Information from those other research studies suggests that this drug may help to treat metastatic breast cancer.
* This study will evaluate whether olaparib is effective in breast cancer patients whose tumor has a mutation in one of the other genes that function with BRCA1 and BRCA2 to repair damaged DNA .This mutation may have been inherited from a parent, or may have developed only in the tumor.
* This study will also evaluate whether olaparib is effective in breast cancer patients whose tumor has a mutation in BRCA1 or BRCA2 that was acquired by the tumor, but not inherited.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:BRCA1/2 Mutation, Brain Metastases, MDS/AML, Others
Must Not Be Taking:PARP Inhibitors, CYP3A Inhibitors
114 Participants Needed
High-Dose Therapy and Autologous Stem Cell Transplant for Non-Hodgkin's Lymphoma
Montvale, New Jersey
This trial is testing how different amounts of a specific type of stem cell affect the outcomes of patients who receive their own stem cells back after treatment. It targets patients undergoing stem cell transplants. The treatment involves collecting, freezing, and re-infusing different amounts of these stem cells to see which dose works best. This method has been used in various clinical trials for treating multiple diseases, including multiple sclerosis and multiple myeloma.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:HIV, Prior Stem Cell Transplant, Others
59 Participants Needed
Pirtobrutinib + Venetoclax + Rituximab for Waldenström's Macroglobulinemia
Montvale, New Jersey
The purpose of this study is to find out if the combination of pirtobrutinib, venetoclax, and rituximab is an effective treatment for participants with Waldenström's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL)
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:HIV, Hepatitis B, Hepatitis C, Others
Must Not Be Taking:Warfarin, CYP3A Inducers
40 Participants Needed
Botensilimab + Balstilimab for Colorectal Cancer
Montvale, New Jersey
The researchers are doing this study to find out whether the combination of botensilimab and balstilimab (BOT/BAL), followed by balstilimab alone, is an effective treatment for people with microsatellite stable (MSS) colon cancer or colorectal liver metastases (CRLM) who have measurable residual disease (MRD) after standard treatment with surgery and chemotherapy.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Metastatic Disease, Autoimmune Disease, Others
Must Not Be Taking:Immunosuppressants, Steroids
284 Participants Needed
E-Nose Technology for Lung Cancer
Montvale, New Jersey
The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure changes in certain chemicals in the breath before and after standard neoadjuvant therapy in people with NSCLC.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:None
50 Participants Needed
Elacestrant + Abemaciclib for Endometrial Cancer
Montvale, New Jersey
The researchers are doing this study to find out whether elacestrant is an effective and safe treatment alone or in combination with abemaciclib for people with advanced or recurrent ER+ endometrial cancer.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Female
Key Eligibility Criteria
Disqualifiers:Visceral Crisis, ILD, Hyperlipidemia, Others
Must Be Taking:LHRH Agonist
75 Participants Needed
Tarlatamab for Prostate Cancer
Montvale, New Jersey
The researchers are doing this study to find out whether tarlatamab is an effective treatment for Delta-like Protein 3 (DLL3)-positive prostate cancer that has spread to other parts of your body (metastasized) and has either come back after treatment (relapsed) or not responded to treatment (refractory).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Male
Key Eligibility Criteria
Disqualifiers:Uncontrolled Hypertension, Seizure History, Active Hepatitis, Others
Must Be Taking:Androgen Deprivation
32 Participants Needed
Teclistamab + RVd for Multiple Myeloma
Montvale, New Jersey
The purpose of this study is to find out whether Tec-RVd (teclistamab, lenalidomide, bortezomib, and dexamethasone) after 3 treatment Cycles of Dara-RVd (daratumumab, lenalidomide, bortezomib, and dexamethasone) is a safe treatment for people with newly diagnosed multiple myeloma (MM).
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Plasma Cell Leukemia, Active Malignancy, Others
65 Participants Needed
Sacituzumab Govitecan + Cetuximab for Throat Cancer
Montvale, New Jersey
The purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Severe Allergies, CNS Metastases, Others
Must Not Be Taking:Topoisomerase Inhibitors
40 Participants Needed
Know someone looking for new options?
Spread the word